Biotechnology News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Ovarian cancer test study: Four-analyte blood test developed by researchers at the Nevada Cancer Institute and Yale University School of Medicine requires "further improvement" before it is to be recommended for population screening of ovarian cancer, they note in the May 10 Proceedings of the National Academy of Sciences. The assay demonstrated 95% sensitivity and 95% specificity in a blinded cross-validation study involving 106 healthy females and 100 patients with epithelial ovarian cancer (EOC). Nevertheless, the study authors cite 99.6% as a desirable threshold for specificity. They advise that "other proteins previously implicated in EOC discrimination" might enhance the assay, which could be offered to high-risk patients. Follow-up evaluations such as transvaginal ultrasound then could be conducted in patients who test positive twice, the researchers note. The test used ELISA and microarray screening analysis, performed by Qiagen...
You may also be interested in...
Pathogen inactivation trial suspended
Vitex "temporarily" halts patient enrollment in a Phase III study exploring use of its Inactine pathogen inactivation system with red blood cells for an acute-only indication. The decision to suspend enrollment comes a little over a month after a data safety monitoring board cleared the trial despite antibody problems found in Vitex' earlier Phase III trial, which supported a chronic infusion claim (1"The Gray Sheet" Oct. 18, 2004, In Brief). The latter trial was halted a year ago. The acute-only study was suspended because of one patient's immune response to Inactine-treated red cells, Vitex says. Antibody issues also have posed hurdles to clinical development of Baxter/Cerus' Intercept...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.